Pedro C. Barata, MD, MSc is a board-certified, fellowship-trained medical oncologist at University Hospitals Seidman Cancer Center and an Associate Professor of Medicine at Case Western Reserve University School of Medicine. His special clinical interests include kidney, prostate and bladder cancers. Dr. Barata is also a renowned clinical trialist and researcher and serves as Director of the Clinical Genitourinary Medical Oncology Research Program at University Hospitals Seidman Cancer Center. His research interests include experimental therapeutics, the molecular profiling of tumors and genomic-based therapies for genitourinary tumors. After completing his fellowship in medical oncology, Dr. Barata came to the United States in 2016 where he completed a clinical fellowship in experimental therapeutics in genitourinary tumors at the Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio. During that time, he also rotated at the phase I / Experimental Therapeutics Department at MD Anderson Cancer Center, Houston, Texas. Dr. Barata is an active member in numerous professional committees and societies, including the American Urological Association, the American Society of Clinical Oncology, the American Association for Cancer Research and the Society for Immunotherapy of Cancer. The recipient of numerous research and education grants, Dr. Barata is a prolific author and co-author, with dozens of published studies and citations to his credit. Most recently, he was named as the Associate Editor of the ASCO Educational Book, an annual publication that serves to educate all members of the oncology care team on practice-changing oncology research so patients can receive the highest-quality, equitable care. Topics for the peer-reviewed articles are selected by ASCO’s Annual Meeting Education Committee and authored by the Annual Meeting Education Program faculty and international experts in oncology. Dr. Barata also serves as the Prostate Cancer Section Editor for the Oncologist journal and is a member of the editorial team of the Translational Oncology journal.